The National Cancer Institute issued two funding opportunityannouncements to create a grant-funded network for early phase cancer prevention trials. Requests for Applications for the Cancer Prevention Clinical Trials Network: CP-CTNet Sites and Cancer Prevention Clinical Trials Network: CP-CTNet Data Management, Auditing, and Coordinating Center were released September 14, 2018; applications are due November 16, 2018.
The CP-CTNet funding opportunity announcements solicit applications from institutions and organizations to participate in the program. More information on announcements RFA-CA-18-029 (CP-CTNet Sites, UG1 Clinical Trial Required) and RFA-CA-18-030 (CP-CTNet Data Management, Auditing, and Coordinating Center (DMACC), U24 Clinical Trial Required) are available on the Division of Cancer Prevention website. This program will replace the current contract-funded Phase 0-I-II Cancer Prevention Program, known as The Consortia.
In addition, the program announced two informational webinars to address questions from potential applicants to be held on Tuesday, October 2 consecutively, from 2:00 pm to 3:00 pm EDT for the UG1 and 3:00 pm to 4:00 pm EDT for the U24. Registration is required and questions may be sent in advance from the registration page or to CPCTNet@mail.nih.gov.
The Cancer Prevention Clinical Trials Network (CP-CTNet) will perform early phase clinical trials to assess the safety, tolerability, and cancer preventive potential of agents and interventions of varying classes, many of which target molecules or processes known to be important during carcinogenesis. These trials include phase 0 (micro-dosing), phase I (dose-finding), and phase II (preliminary efficacy) clinical trials. The goal is to identify safe and effective preventive interventions in order to advance their further clinical development for cancer prevention.
The overall goal of CP-CTNet is to perform early phase cancer prevention clinical trials to identify agents and interventions that can advance through the various phases of clinical development. Specific objectives are summarized below:
- To efficiently design and conduct early phase clinical trials to assess the cancer preventive potential of a variety of different agents or strategies. Emphasis is on novel agents and interventions that target relevant pathways important in carcinogenesis.
- To characterize the effects of these agents and interventions on their molecular targets, as well as on other biological events associated with cancer development (such as cell proliferation, apoptosis, growth factor expression, oncogene expression, immune response) and correlate these effects with clinical endpoints.
- To develop further scientific insights into the mechanism of cancer prevention by the agent or strategy examined and to continue to develop novel potential markers as determinants of response.